

LUMENIS

Healing Warriors: Treating Traumatic Scars with ULTRApulse α

While deployed in Southern Afghanistan, Army Staff Sergeant (SSG) Daniel Burgess stepped on an Improvised Explosive Device (IED). The blast caused multiple injuries, most noticeably the loss of his right leg and a complete degloving of his left.

Recovering from extensive, life-threatening injuries is a long and demanding journey. SSG Burgess approached the process with the same grit he used throughout his military career. He worked hard, learned to walk with a prosthetic, and made rehabilitation his new mission. But one aspect hindered his progress both physically and mentally – the condition of his remaining leg.

Burgess experienced a great deal of pain in his left leg and the extreme scarring limited his mobility. “It was so bad, that I considered my prosthetic as my good leg,” Burgess said. In addition to the loss of mobility, the leg’s damaged tissue had little blood flow and an open wound that refused to heal. The problem reached the point where Burgess considered that amputation could provide a better solution. Then Burgess met three pioneers of scar rehabilitation, Dr. Chad Hivnor, Dr. Peter Shumaker, and Dr. Thomas Beachkofsky, and began undergoing treatment with advanced CO2 technology from Lumenis.



Burgess experienced a great deal of pain in his left leg and the extreme scarring limited his mobility. “It was so bad, that I considered my prosthetic as my good leg,”

— Sgt. Daniel Burgess



“Daniel has responded very well to treatments and has seen reduction in pain, pruritic and improvements in range of motion and tissue pliability. These improvements while impressive are not unique to his case and are very reproducible in other cases. I hope his story will inspire and encourage others in need to seek such care.”

- Dr. Thomas M. Beachkofsky



Since the first treatment in 2012 (including a four-year gap during which treatment was not available), Burgess has experienced dramatic improvement. “The laser treatments have completely changed my life,” Burgess said. “My leg has blood flow... and the scar has released like crazy.” The benefit of improved mobility means restored dependency on his remaining leg and, far more important, enjoying more activities with his ever-supportive wife and daughters.

“Burgess responded right away with loosening of the skin with flexibility and improvement of non-healing wounds due to tension,” said Dr. Chad Hivnor, who along with Dr. Peter Schumaker and Dr. Beachkofsky treated Burgess post injury with Lumenis CO2 technology. Hivnor continued, “He demonstrates the regenerative aspect of the laser for the scar and the improvement of the overall function of the skin.”

Burgess emphasized that the treatments were relatively quick and performed using only topical



anesthetic even though the treatment is considered aggressive. Post-treatment downtime is only a day or two, much quicker than other treatments such as skin grafting. Given the ease of treatment and the cumulative improvements, Burgess plans to continue rehabilitating his scar with expert provider Dr. Thomas Beachkofsky. Additionally, Burgess is spreading the word about the novel treatment.

“I don’t mind sharing my story as long as it serves other patients out there,” he said. “If they become aware of treatments that are this effective, it’s a win for all.”

The technology that Burgess credits is from Lumenis, the innovative pioneer who introduced fractionated CO2 to aesthetics and continues to hold the gold standard position in the industry. Lumenis’ most advanced CO2 platform, the ULTRApulse Alpha, is now available in the US. Most recently, Lumenis announced the creation of its Government, Burn, and Hospital division (GBH), a commitment to making its technology available for patients everywhere.



Dr. Chad Hivnor, Dr. Peter Shumaker, Sandra Woods PA-C & Dr. Thomas Beachkofsky -Photo courtesy of Dr. Chad Hivnor

ULTRApulse α



WARNINGS AND RISKS

CO₂ lasers are intended solely for use by professionals trained in the use of the Carbon Dioxide laser (10.6 μ m) wavelength. Incorrect treatment settings or misuse of the technology can present risk of serious injury to patient and operating personnel. Risks that may be associated with any CO₂ laser procedure may include change of pigmentation, infection, erythema, skin induration or scarring. Read and understand the CO₂ systems and accessories operator manuals for a complete list of intended use, contraindications, and risks. The use of Lumenis® CO₂ laser is contraindicated where a patient has taken Accutane (Isotretinoin) within the past 6–12 months, has a history of keloid formation and demonstrate excessive or unusually prolonged erythema.

© 2024 All Rights Reserved. The Lumenis Be Group of Companies. Lumenis, its logo, UltraPulse, ActiveFX, DeepFX, TotalFX and SCAAR FX are trademarks or registered trademarks of the Lumenis Be Group of Companies. Specifications are subject to change without notice.

Manufactured for Lumenis Be Ltd.
Yokneam Industrial Park
Hakidma Street 9, P.O.B. # 426
Yokneam 2069236, ISRAEL
Tel: +972 77 959 9000

Lumenis (Germany) GmbH
Heinrich-Hertz-Str 3 D-63303
Dreieich-Dreieichenhain
Germany

EMEA
Dreieich Dreieichenhain, Germany
T +49 6103 8335 0
F +49 6103 8335 300


Hertfordshire, UK
T +44 20 8736 4110
F +44 20 8736 4119

JAPAN
Tokyo, Japan
T +81 3 6743 8300
F +81 3 6743 8301

AMERICAS
San Jose, CA, USA
T +1 408 764 3000
+1 877 586 3647
F +1 408 764 39990

ASIA PACIFIC
Beijing, China
T + 86 10 5737 6677
F +86 10 5737 6767

Gurgaon, India
T + 91 124 422 07 95
Kowloon, Hong Kong
T + 852 217 428 00
F + 852 272 251 5



CE0483